PharmaTimes: News RSS
- First patient dosed in Gyroscope Therapeutics’ AMD study
- Report finds NICE’s routine appraisals need reform
- Emergex to drive vaccine development with R&D facility and new hire
- Keytruda combination found to reduce risk of death in RCC
- NovaBiotics given £1.8m to advance Novamycin
- Opdivo shows promising results in Phase I/II trial
- EMA suspends fenspiride medicines due to heart rhythm risks
- UCB to form a research satellite facility within King’s College London
- Innovate UK awards AKLRD £675,000 for osteoarthritis drug
- Darolutamide shows promise for treatment of prostate cancer
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
Leave a Reply
Want to join the discussion?Feel free to contribute!